Wednesday, 27 October 2021


Prestige Biopharma to open vaccine production centre in South Korea

20 April 2021 | News

Projected to start operations from August 2021

Image credit- businesswire

Image credit- businesswire

Prestige Biopharma Limited (PBP), based in Singapore, has announced that the company will be introducing a vaccine development and production centre into its core business.

PBP has been preparing for a business expansion into the development of vaccine-based therapeutics since the start of the ongoing COVID-19 outbreak as a response to the current, and potential future, viral pandemics. The design, development and implementation of the vaccine centre has resulted from that plan.

PBP is on target to complete the construction of its global-scale vaccine production facility in Osong, South Korea with a total area of approximately 8,500 m2 inside the Campus 2 facility of its affiliated company Prestige Biologics.

The vaccine centre initiated construction last month (March 2021) and is projected to start operations from August 2021 utilizing Prestige Biologics’ unmatched engineering service for expedited establishment with cutting-edge technology.

PBP will be utilising Prestige Biologics’ proprietary ALITA Smart BioFactory™, the world’s first smart factory system in biomanufacturing designed based on digital artificial intelligence, which will contribute to reducing human or process related errors.

The system will also enable fast and convenient change-over to maximize efficiency when catering for multiple products and manufacturing processes. This smart factory’s ‘single-use’ system will enable mass production of vaccine in the short-term.

The total production capacity of the vaccine centre is 100,000 litres, comprised of 50 units of 2,000 litre single-use bioreactors with accompanying seed train and down-stream purification capacities. With this global-scale production capacity, the centre will contribute to the growing global demands of vaccine development and production in response to infectious diseases such as COVID-19.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account